William Gray

William A. Gray, M.D. FACC FSCAI
System Chief, Division of Cardiovascular Diseases of Main Line Health
President, Lankenau Heart Institute

William A. Gray, M.D., is an interventional cardiologist, board certified in internal medicine, interventional cardiology, vascular and endovascular medicine. Dr. Gray was at the Center for Interventional Vascular Therapy as Director, Endovascular Intervention at New York Columbia-Presbyterian Hospital.

Prior to joining Columbia University Dr. Gray was Director of the Endovascular Care at Swedish Medical Center from 1999-2005. Before Seattle, Dr. Gray practiced at Southwest Cardiology where he directed research, served as vice-chair of the Cardiology division at Presbyterian Hospital in Albuquerque, N.M., and was a founding member of the Heart Hospital of New Mexico.

Dr. Gray specializes in cardiac/structural and peripheral arterial disease diagnosis and treatment as well as non-surgical modalities for stroke prevention, research into preventing the reoccurrence of disease following successful angioplasty or stenting.

Dr. Gray has been principal investigator for numerous clinical trials, and is routinely asked to speak at national and international conferences. He has also been a consultant and device/procedure proctor for numerous medical corporations, and has been a journal reviewer for the American Medical Association.

Dr. Gray holds a bachelor’s degree in Chemistry from Dickinson College in Carlisle, PA and graduated from Temple University’s School of Medicine in Philadelphia. Dr. Gray’s postgraduate training included an internship, residency, and Chief Residency in Internal Medicine at Brown University/Rhode Island Hospital in Providence, R.I., where he also completed a clinical/research/ interventional fellowship in Cardiology.

William A. Gray, M.D. FACC FSCAI
System Chief, Division of Cardiovascular Diseases of Main Line Health
President, Lankenau Heart Institute

William A. Gray, M.D., is an interventional cardiologist, board certified in internal medicine, interventional cardiology, vascular and endovascular medicine. Dr. Gray was at the Center for Interventional Vascular Therapy as Director, Endovascular Intervention at New York Columbia-Presbyterian Hospital.

Prior to joining Columbia University Dr. Gray was Director of the Endovascular Care at Swedish Medical Center from 1999-2005. Before Seattle, Dr. Gray practiced at Southwest Cardiology where he directed research, served as vice-chair of the Cardiology division at Presbyterian Hospital in Albuquerque, N.M., and was a founding member of the Heart Hospital of New Mexico.

Dr. Gray specializes in cardiac/structural and peripheral arterial disease diagnosis and treatment as well as non-surgical modalities for stroke prevention, research into preventing the reoccurrence of disease following successful angioplasty or stenting.

Dr. Gray has been principal investigator for numerous clinical trials, and is routinely asked to speak at national and international conferences. He has also been a consultant and device/procedure proctor for numerous medical corporations, and has been a journal reviewer for the American Medical Association.

Dr. Gray holds a bachelor’s degree in Chemistry from Dickinson College in Carlisle, PA and graduated from Temple University’s School of Medicine in Philadelphia. Dr. Gray’s postgraduate training included an internship, residency, and Chief Residency in Internal Medicine at Brown University/Rhode Island Hospital in Providence, R.I., where he also completed a clinical/research/ interventional fellowship in Cardiology.

Ajay Kirtane, MD, SM, is a Professor of Medicine at Columbia University Medical Center and Director of the Columbia Interventional Cardiovascular Care Center at NYPresbyterian Hospital. Dr. Kirtane is a graduate of Princeton University and Columbia University College of Physicians and Surgeons, and completed his residency/chief residency in Internal Medicine at the University of California – San Francisco. He completed fellowships in Cardiovascular Disease,Coronary and Peripheral Vascular Intervention at Beth Israel Deaconess Medical Center / Harvard Medical School and has a Masters of Science in Clinical Epidemiology from the Harvard School of Public Health.

Dr. Kirtane is a practicing Cardiologist with an interest in coronary and peripheral intervention and assumed the directorship of the NYP/Columbia cardiac cath laboratories in 2015. In addition to his clinical commitments at CUMC, Dr. Kirtane has a strong interest in clinical education and research, serving as Chief Academic Officer of the Center for Interventional Vascular Therapy. On the national and international level, he is a co-director of the Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics meeting, has served as a director of several international, national, and regional educational meetings, and has participated on the program committees for the scientific sessions of both the American College of Cardiology and American Heart Association. Dr. Kirtane’s research interests are in clinical trial methodology and outcomes of device-based and pharmacologic interventions in Interventional Cardiology. He has authored/co-authored >150 original manuscripts and >50 reviews and chapters including the “Coronary Stenting” chapters of the two most widely used textbooks in Interventional Cardiology.

Dr. Patrick Muck attended the University of Notre Dame and completed medical school at the University of Kentucky. He completed his vascular fellowship at Good Samaritan Hospital in Cincinnati, Ohio. He currently is the Program Director of the independent and integrated vascular residencies at Good Samaritan Hospital in Cincinnati, Ohio. Dr. Muck is also the Chief of the Section of Vascular Surgery at Good Samaritan Hospital. He is the Site Director for multiple FDA trials at GSH. Dr. Muck has been a speaker and/or moderator at many national and international meetings. He has written and published articles in peer reviewed journals and currently is a reviewer for the Journal of Vascular Surgery. He has authored several book chapters as well. He serves as the Past President for the Midwestern Vascular Surgery Society. He is the Treasurer of the American Venous Forum.

I am currently the Lead Interventional Medical Physics Expert at Nottingham University Hospitals NHS Trust [having retired and returned!] and also a recent President of the British Institute of Radiology. I currently chair the UK working group investigating how best to set DRLs in interventional procedures. I was recently a member of an ICRP working group that has published a report on Diagnostic Reference Levels. I have been co-opted on to two international WG’s looking at quality control of radiological equipment in general [IEC] and angiography imaging equipment [EFOMP] both of which were published last year. I was seconded on to a US NCRP WG on training requirements for fluoroscopists [NCRP Commentary #33] and am part of the research team writing EU guidance for Incident Learning Systems. My current research interests are patient skin [Adviser to IAEA international study], and staff dose assessment and optimisation in interventional cardiology and radiology. I am currently part of a team within the British Society of Interventional Radiology looking to increase awareness of staff protection issues in interventional procedures.

Lancer Smith, MS, is a health physicist and the founder of Heartland Physics, a medical and health physics consulting company based in Alabama. He also serves as the Health Physics Lead at the University of Alabama at Birmingham (UAB), overseeing radiation safety for a wide range of clinical and research applications. With a master’s degree in health physics, Lancer specializes in radiation shielding design, equipment performance testing, and regulatory compliance for diagnostic imaging systems using X-rays, including fluoroscopy.

In his institutional role and private practice, Lancer is passionate about helping facilities optimize radiation safety programs while maintaining clinical efficiency. His work frequently involves evaluating radiation safety policies and procedures and educating healthcare providers on radiation exposure reduction strategies.

Lancer’s dual perspective—working within large healthcare systems and independently with private practices—gives him unique insight into the practical implementation of radiation safety protocols across diverse clinical settings. He believes that real-time dosimetry is critical for cultivating a culture of safety in fluoroscopy and improving occupational dose awareness for physicians and staff.

President, ORSIF
Founder & CMO, Rampart IC

Robert Foster MD is an Interventional cardiologist specializing in peripheral endovascular procedures at The Vein Company in Kingsport TN. He practiced as an IC with Birmingham Heart Clinic, in Birmingham Alabama, for 26 years with special interest in peripheral arterial and venous disease before becoming the Chief Medical Officer for Rampart IC. and the President of ORSIF

Dr. Foster is a graduate of Baylor University and received his medical degree from UAB. After residency at UT Southwestern, he returned to UAB for cardiology fellowship. He then went on staff at UAB as the Clinical Director of Cardiac MRI before joining the Birmingham Heart Clinic.

Dr. Foster’s passion now is creating the safest interventional lab environments to protect physicians and staff from the harmful effects of radiation while reducing orthopedic strain and injury.

Dr Bella Hausen obtained her medical degree from the universities of Manchester and Edinburgh where she was initially a plastic surgical trainee with an interest in micro vascular repair. She completed advance microsurgical training at Zurich, and Rhainoplasty Msc at Barcelona. She went on to complete her Radiology and Interventional Radiology specialist registration with the royal college of Radiology London U.K. She completed her advance Endovascular fellowship with Professor Andrew Holden at Auckland University hospital, NewZealand.

Dr Hausen preformed the first lithotripsy in peripheral endovascular CLI disease, along with the first Sirolimus DCB use in both CLI and AVF, in Europe.

Dr Huasen is the head of endovascular research and innovation in Lancashire U.K. Her current interest are training and education of future doctors, radiation protection for patients and staff, CLI management, AVF salvage, pain management and women’s health. She currently works at Lancashire University health trusts U.K.